Neuroblastoma is the most common pediatric malignancy diagnosed in the first year of life. More than one-half of these children have disseminated disease at the time of diagnosis. Magnetic resonance imaging (MRI) is crucial in the diagnostic imaging evaluation of neuroblastoma, however, no neuroblastoma-specific MRI contrast agents currently exist. We propose to create neuroblastoma-specific MRI contrast agents by conjugating low-molecular weight peptide ligands (<2000 MW) that bind to the surface of neuroblastoma cells with monocrystalline iron oxide nanoparticles (MIONs). In addition to their ease of synthesis, low-molecular weight ligands have several attractive pharmacological and biochemical properties, including rapid biodistribution, excellent tissue penetration, and lack of immunogenicity. MIONs are ultrasmall (approximately 20 nm hydrodynamic radius) dextran-coated iron oxide superparamagnetic colloids that alter T2-weighted MRI contrast enhancement. Recent reports have suggested that MIONs can be conjugated to peptides and proteins to generate cell-specific contrast enhancement. ? ? To generate neuroblastoma-specific MRI imaging reagents, we will employ the following systematic approach. The conjugation of peptides to MIONs will be optimized using a previously described neuropeptide Y1 (NPY-1)-Iike molecule that binds with high affinity to neuroblastoma cells. Complete in vitro characterization of the MION/NPY-1 conjugate will be performed including binding affinity, kinetics, sub-cellular localization, and MRI contrast enhancement of living cells. In addition, NPY/MION conjugates will be evaluated in vivo using human neuroblastoma tumor xenografts established in nu/nu mice. Since NPY-1 has relative, but not absolute specificity for neuroblastoma cells, we will, in parallel, search for novel peptide ligands that bind to the surface of these cells. Using differential peptide phage display screening of two cell lines, one an aggressive neuroblastoma and the other its chemically-differentiated benign counterpart, we will attempt to discover peptides specific for the malignant phenotype. Conjugation of these novel peptides to MIONs could result in contrast agents with higher specificity than is possible with NPY-1 derivatives. ? ? As imaging technologies such as MRI have continued to improve, the integration of basic genetic and molecular biologic discoveries into development of novel tissue-specific contrast agents has lagged behind. This study presents a generalizable approach to producing tumor cell-specific MRI contrast reagents, and should permit improved diagnosis, and hence treatment, of neuroblastoma in children.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Clinical Investigator Award (CIA) (K08)
Project #
5K08CA093554-05
Application #
7013158
Study Section
Subcommittee G - Education (NCI)
Program Officer
Lohrey, Nancy
Project Start
2002-09-27
Project End
2007-08-31
Budget Start
2006-03-24
Budget End
2007-02-28
Support Year
5
Fiscal Year
2006
Total Cost
$131,220
Indirect Cost
Name
Children's Hospital Boston
Department
Type
DUNS #
076593722
City
Boston
State
MA
Country
United States
Zip Code
02115
Dearling, Jason L J; Paterson, Brett M; Akurathi, Vamsidhar et al. (2015) The ionic charge of copper-64 complexes conjugated to an engineered antibody affects biodistribution. Bioconjug Chem 26:707-17
Dearling, Jason L J; Voss, Stephan D; Dunning, Patricia et al. (2011) Imaging cancer using PET--the effect of the bifunctional chelator on the biodistribution of a (64)Cu-labeled antibody. Nucl Med Biol 38:29-38
Mulkern, Robert V; Salsberg, Sandra Loeb; Krauel, Marta Ramon et al. (2008) A paradoxical signal intensity increase in fatty livers using opposed-phase gradient echo imaging with fat-suppression pulses. Pediatr Radiol 38:1099-104
Lee, Edward Y; Vargas, Sara O; Sawicki, Gregory S et al. (2007) Mucoepidermoid carcinoma of bronchus in a pediatric patient: (18)F-FDG PET findings. Pediatr Radiol 37:1278-82
Voss, Stephan D; Smith, Suzanne V; DiBartolo, Nadine et al. (2007) Positron emission tomography (PET) imaging of neuroblastoma and melanoma with 64Cu-SarAr immunoconjugates. Proc Natl Acad Sci U S A 104:17489-93
Lee, E Y; Dillon, J E; Callahan, M J et al. (2006) 3D multidetector CT angiographic evaluation of extralobar pulmonary sequestration with anomalous venous drainage into the left internal mammary vein in a paediatric patient. Br J Radiol 79:e99-102
Mulkern, Robert V; Hung, Yin P; Ababneh, Zaid et al. (2005) On the strong field dependence and nonlinear response to gadolinium contrast agent of proton transverse relaxation rates in dairy cream. Magn Reson Imaging 23:757-64